Focused On-demand Library for Sorting nexin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y5X0

UPID:

SNX10_HUMAN

Alternative names:

Alternative UPACC:

Q9Y5X0; E9PFH5; Q8IYT5

Background:

Sorting nexin-10, identified by the accession number Q9Y5X0, plays a pivotal role in protein sorting and membrane trafficking within endosomes. It is crucial for cilium biogenesis, regulating the transport and localization of specific proteins to the cilium, including V-ATPase subunits and RAB8A. This protein is also instrumental in osteoclast differentiation, impacting bone resorption.

Therapeutic significance:

Sorting nexin-10's involvement in osteopetrosis, autosomal recessive 8, underscores its therapeutic potential. The disease, characterized by dense bones and impaired osteoclast function, highlights the protein's critical role in bone resorption. Understanding the role of Sorting nexin-10 could open doors to potential therapeutic strategies for treating osteopetrosis and related bone density disorders.